Ching‐Wei D. Tzeng

Author

Ching‐Wei D. Tzeng

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

C. David Tzeng, C. Tzeng, C.D. Tzeng, CHING-WEI D. TZENG, Ching-Wei D Tzeng, Ching-Wei D. Tzeng, Ching-Wei David Tzeng, Ching-Wei Tzeng, Ching‐Wei D. Tzeng, Ching‑Wei D. Tzeng

615

Publications

9.9K

Citations

H-Index

129

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center University of Kentucky

About

Ching‐Wei D. Tzeng is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, surgical oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	95	5.2K
2	Health Sciences	17	19	848
3	Public Health	6	6	142
4	Nursing	2	2	53
5	Engineering	1	1	34

Ching‐Wei D. Tzeng

168

Publications

8.9K

Citations

H-Index

Page 1

	Year	Citations
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes Erick Riquelme, Yu Zhang, Liangliang Zhang, Cell DysbiosisPancreatic CancerTumor Microbiome DiversityMedicineGut Microbiology	2019	1.5K
Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression Vincent Bernard, Alexander Semaan, Jonathan Huang, Clinical Cancer Research	2018	397
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial Ahmed O. Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, The Lancet. Gastroenterology & hepatology	2022	241
Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival Ching‐Wei D. Tzeng, Hop S. Tran Cao, Jeffrey E. Lee, Journal of Gastrointestinal Surgery Surgical OncologyPancreatic CancerGastrointestinal OncologyMultimodality Therapy CompletionMedicine	2013	193
Optimal Future Liver Remnant in Patients Treated with Extensive Preoperative Chemotherapy for Colorectal Liver Metastases Junichi Shindoh, Ching‐Wei D. Tzeng, Thomas A. Aloia, Annals of Surgical Oncology Surgical OncologyHepatologyColorectal Liver MetastasesPatients TreatedMedicine	2013	186
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma Giampaolo Perri, Laura Prakash, Wei Qiao, JAMA Surgery	2020	173
Predictors of morbidity and mortality after hepatectomy in elderly patients: analysis of 7621 NSQIP patients Ching‐Wei D. Tzeng, Amanda Cooper, Jean‐Nicolas Vauthey, HPB HepatologyElderly PatientsGeriatricsGastroenterologyOutcomes Research	2013	171
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer Ching‐Wei D. Tzeng, Aparna Balachandran, Mediha Ahmad, HPB Surgical OncologySerum Carbohydrate AntigenPancreatic CancerNeoadjuvant TherapyGastrointestinal Oncology	2013	171
Mutation Status of <i>RAS, TP53</i> , and <i>SMAD4</i> is Superior to Mutation Status of <i>RAS</i> Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases Yoshikuni Kawaguchi, Scott Kopetz, Timothy E. Newhook, Clinical Cancer Research	2019	171
Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases Yun Shin Chun, Guillaume Passot, Suguru Yamashita, Annals of Surgery	2017	163

Page 1